L-365,260 inhibits in vitro acid secretion by interacting with a PKA pathway

Br J Pharmacol. 1999 May;127(1):259-67. doi: 10.1038/sj.bjp.0702505.

Abstract

The aim of this study was to analyse the antisecretory mechanism of L-365,260 in vitro in isolated rabbit gastric glands. We showed that compound L-365,260, described as a non-peptide specific competitive CCK-B receptor antagonist, was able to dose-dependently inhibit [14C]-aminopyrine accumulation induced by histamine (10(-4) M), carbachol (5x10(-5) M), 3-isobutyl-1-methyl-xanthine (IBMX) (5x10(-6) M) and forskolin (5x10(-7) M) with similar IC50 values respectively of 1.1+/-0.6x10(-7) M, 1.9+/-1.2x10(-7) M, 4.2+/-2.0x10(-7) M and 4.0+/-2.8x10(-7) M. We showed that L-365,260 acted beyond receptor activation and production of intracellular second messengers and that it had no action on the H+/K+ -ATPase. We found that L-365,260 inhibited cyclic AMP-induced [14C]-aminopyrine accumulation in digitonin-permeabilized rabbit gastric glands, suggesting that this compound acted, at least in part, as an inhibitor of the cyclic AMP-dependent protein kinase (PKA) pathway.

MeSH terms

  • Aminopyrine / metabolism
  • Animals
  • Benzodiazepinones / pharmacology*
  • Cyclic AMP / biosynthesis
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors*
  • Enzyme Inhibitors / pharmacology*
  • Gastric Acid / metabolism*
  • Gastric Mucosa / drug effects
  • Gastric Mucosa / enzymology
  • Gastric Mucosa / metabolism
  • Histamine H2 Antagonists / pharmacology
  • In Vitro Techniques
  • Inositol Phosphates / metabolism
  • Omeprazole / pharmacology
  • Phenylurea Compounds / pharmacology*
  • Proton Pump Inhibitors
  • Rabbits
  • Receptors, Cholecystokinin / antagonists & inhibitors*
  • Second Messenger Systems / drug effects

Substances

  • Benzodiazepinones
  • Enzyme Inhibitors
  • Histamine H2 Antagonists
  • Inositol Phosphates
  • Phenylurea Compounds
  • Proton Pump Inhibitors
  • Receptors, Cholecystokinin
  • Aminopyrine
  • L 365260
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • Omeprazole